IL118836A - Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan - Google Patents

Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Info

Publication number
IL118836A
IL118836A IL11883696A IL11883696A IL118836A IL 118836 A IL118836 A IL 118836A IL 11883696 A IL11883696 A IL 11883696A IL 11883696 A IL11883696 A IL 11883696A IL 118836 A IL118836 A IL 118836A
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
aminoindan
disease
propargyl
injury
Prior art date
Application number
IL11883696A
Other languages
English (en)
Other versions
IL118836A0 (en
Original Assignee
Teva Pharma
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Technion Res & Dev Foundation filed Critical Teva Pharma
Priority to IL11883696A priority Critical patent/IL118836A/xx
Publication of IL118836A0 publication Critical patent/IL118836A0/xx
Priority to HU9904525A priority patent/HU226961B1/hu
Priority to AT97927353T priority patent/ATE328590T1/de
Priority to JP50580698A priority patent/JP4368421B2/ja
Priority to EP97927353A priority patent/EP0929298B1/en
Priority to CA002260037A priority patent/CA2260037C/en
Priority to PCT/IL1997/000205 priority patent/WO1998002152A1/en
Priority to DE69736066T priority patent/DE69736066T2/de
Priority to AU31880/97A priority patent/AU3188097A/en
Priority to CNB971971994A priority patent/CN1149985C/zh
Priority to NO19990088A priority patent/NO326052B1/no
Priority to US09/228,153 priority patent/US6277886B1/en
Publication of IL118836A publication Critical patent/IL118836A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11883696A 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan IL118836A (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
CNB971971994A CN1149985C (zh) 1996-07-11 1997-06-20 含s-(-)-n-炔丙基-1-氨基茚满的药物组合物
EP97927353A EP0929298B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
AT97927353T ATE328590T1 (de) 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(- )-n-propargyl-1-aminoindan
JP50580698A JP4368421B2 (ja) 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物
HU9904525A HU226961B1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
CA002260037A CA2260037C (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
DE69736066T DE69736066T2 (de) 1996-07-11 1997-06-20 Pharmazeutische zusammensetzungen enthaltend s-(-)-n-propargyl-1-aminoindan
AU31880/97A AU3188097A (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan
NO19990088A NO326052B1 (no) 1996-07-11 1999-01-08 Anvendelse av S-(-)-N-propargyl-1-aminoindamin eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament (a) for behandling av neurotrauma eller (b) for forbedring av hukommelsen hos en post-CHI-pasient.
US09/228,153 US6277886B1 (en) 1996-07-11 1999-01-11 Pharmaceutical compositions comprising S-(−)-N-propargyl-1-aminoindan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Publications (2)

Publication Number Publication Date
IL118836A0 IL118836A0 (en) 1996-10-31
IL118836A true IL118836A (en) 2001-01-11

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Country Status (12)

Country Link
US (1) US6277886B1 (Direct)
EP (1) EP0929298B1 (Direct)
JP (1) JP4368421B2 (Direct)
CN (1) CN1149985C (Direct)
AT (1) ATE328590T1 (Direct)
AU (1) AU3188097A (Direct)
CA (1) CA2260037C (Direct)
DE (1) DE69736066T2 (Direct)
HU (1) HU226961B1 (Direct)
IL (1) IL118836A (Direct)
NO (1) NO326052B1 (Direct)
WO (1) WO1998002152A1 (Direct)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1372664A1 (en) 2001-03-01 2004-01-02 Hollis-Eden Pharmaceuticals Inc. Use of certain steroids for treatment of blood cell deficiencies
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
WO2004041151A2 (en) * 2002-11-07 2004-05-21 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
PT1567152E (pt) 2002-11-15 2013-10-03 Teva Pharma Uso de rasagilina com riluzol para tratar a esclerose lateral amiotrófica
EP2433626B1 (en) 2003-11-25 2015-11-04 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
CA2574925A1 (en) * 2004-07-26 2006-02-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical dosage forms including rasagiline
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
EP2471536A1 (en) 2004-09-29 2012-07-04 Harbor BioSciences, Inc. Steroid analogs and characterization and treatment methods
ES2420404T3 (es) * 2005-02-17 2013-08-23 Teva Pharmaceutical Industries Ltd. Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2632638T3 (es) 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
NZ571591A (en) 2006-04-03 2011-09-30 Teva Pharma Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
HRP20110980T1 (hr) * 2006-12-14 2012-02-29 Teva Pharmaceutical Industries Ltd. Kristalna kruta rasagilinska baza
WO2008076315A1 (en) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
US20090062400A1 (en) * 2007-09-05 2009-03-05 Laurence Oron Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
CA2727022A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries Ltd. Rasagiline for parkinson's disease modification
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
JP2011524907A (ja) 2008-06-19 2011-09-08 テバ ファーマシューティカル インダストリーズ リミティド 固体ラサギリン塩基を調製および乾燥する方法
US20100189788A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
RU2607595C2 (ru) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
CA2806740A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
US8691872B2 (en) 2010-07-27 2014-04-08 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
JP2014534196A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
EP2766004A4 (en) 2011-10-10 2015-04-22 Teva Pharma R (+) - N-methyl-propargyl-aminoindan
BR112015003451A2 (pt) 2012-08-17 2017-07-04 Teva Pharma formulação parentérica de rasagilina
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) * 1991-10-16 2001-11-25 Teva Pharma Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
JP4782252B2 (ja) * 1994-01-10 2011-09-28 テバ ファーマシューティカル インダストリーズ リミテッド １−アミノインダン及びこれらの組成物
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
NO990088D0 (no) 1999-01-08
CN1149985C (zh) 2004-05-19
NO326052B1 (no) 2008-09-08
HU226961B1 (en) 2010-03-29
CA2260037A1 (en) 1998-01-22
HUP9904525A3 (en) 2000-12-28
HUP9904525A2 (hu) 2000-11-28
WO1998002152A1 (en) 1998-01-22
ATE328590T1 (de) 2006-06-15
CA2260037C (en) 2007-01-23
CN1227486A (zh) 1999-09-01
NO990088L (no) 1999-03-10
EP0929298B1 (en) 2006-06-07
DE69736066T2 (de) 2006-12-28
IL118836A0 (en) 1996-10-31
JP4368421B2 (ja) 2009-11-18
US6277886B1 (en) 2001-08-21
JP2000514453A (ja) 2000-10-31
EP0929298A1 (en) 1999-07-21
DE69736066D1 (de) 2006-07-20
AU3188097A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
IL118836A (en) Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
HU913447D0 (en) Medical preparations and their use in treating neurologic disorders
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
MX9708977A (es) Uso de r-enantiomero de sales de n-propargilo-1-aminoindano, y composiciones de las mismas.
CA2114251A1 (en) Igf-1 to improve the neural condition
NL300205I2 (nl) N-enentiomeer van N-propargyl-1-aminoindaan voor de behandeling van
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
EP1466606A3 (en) Use of inosine for the manufacture of a medicament for stimulating axonal outgrowth of central nervous system neurons
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
CA2122058A1 (en) Tgf-beta to improve neural outcome
WO1999045011A8 (en) Glycine transport inhibitors
HU9303748D0 (en) Composition of l-dopa-esters
CA2148194A1 (en) Cyclopeptides of the formula i
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
CA2139385A1 (en) Products containing g-csf and tnf binding protein
CA2374997A1 (en) Il6ril6 chimera for the treatment of neurodegenerative diseases
MXPA01009384A (es) Composiciones farmaceuticas que comprenden un derivado de pirimidina y ciclodextrina.
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
NZ268039A (en) Use of efaroxan in treating parkinson's disease
CA2097878A1 (en) Therapeutic agent for neutropenia
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
EP1712231A3 (en) Method for improving the pharmacokinetics of tipranavir

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees
NE Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired